middle.news
Argent BioPharma Completes CannPal Acquisition, Secures Neuvis® Platform Option
9:06am on Monday 13th of April, 2026 AEST
•
Healthcare
Read Story
Argent BioPharma Completes CannPal Acquisition, Secures Neuvis® Platform Option
9:06am on Monday 13th of April, 2026 AEST
Key Points
Acquisition of CannPal's Phase 3 veterinary epilepsy programme completed
Option secured for Neuvis® drug delivery platform to enhance pipeline assets
CannPal asset strengthens clinical and regulatory data supporting CannEpil®
Transaction aligns with Argent’s U.S. national exchange listing strategy
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Argent Biopharma (ASX:RGT)
OPEN ARTICLE